Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

SHE/300759 stock hub

SHE/300759 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

SHE/300759is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

46.1B

Shenzhen Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

SHE/300759

In the news

Latest news · SHE/300759

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E21.3

P25 17.1P50 24.2P75 37.8

Trailing P/E28.7

P25 23.5P50 41.3P75 83.2

ROE10

P25 -0.9P50 4.1P75 8.8

ROIC8.1

P25 -0.5P50 5P75 11.4

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All SHE/300759 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

236

Groups with data

Currency

CNY

Showing 236 of 236 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	China
Country code	CN
Employees	25,088
Employees Change	3,718%
Employees Change Percent	17.4
Enterprise value	CNY 50.9B
Exchange	Shenzhen Stock Exchange
Financial currency	CNY
First seen	2026-05-10
Industry	Biotechnology
Isin	CNE100003JW4
Last refreshed	2026-05-10
Market cap	CNY 46.1B
Price	CNY 27.21
Price currency	CNY
Rev Per Employee	580,942.66x
Sector	Healthcare
Sic	8731
Symbol	she/300759
Website	https://www.pharmaron.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	3.67%
EV Earnings	30.05x
EV/EBIT	24.56x
EV/EBITDA	15.57x
EV/FCF	181.69x
EV/Sales	3.49x
FCF yield	0.61%
Forward P/E	21.34x
P/B ratio	2.69x
P/E ratio	28.66x
P/S ratio	3.16x
PE Ratio10 Y	54.34x
PE Ratio3 Y	27.15x
PE Ratio5 Y	44.24x
PEG ratio	1.43x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	14.22%
EBITDA Margin	21.35%
FCF margin	1.92%
Gross margin	34.38%
Gross Profit	CNY 5B
Gross Profit Growth	15.04%
Gross Profit Growth Q	11.5%
Gross Profit Growth3 Y	7.41%
Gross Profit Growth5 Y	18.82%
Net Income	CNY 1.7B
Net Income Growth	-9.35%
Net Income Growth Q	9.75%
Net Income Growth Quarters	3%
Net Income Growth Years	0%
Net Income Growth3 Y	4.75%
Net Income Growth5 Y	5.16%
Pretax Margin	13.46%
Profit Margin	11.62%
Profit Per Employee	CNY 67,510
Profitable Years	12
ROA	4.9
Roa5y	5.02
ROCE	10.27
ROE	9.99
Roe5y	13.13
ROIC	8.1
Roic5y	10.85

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	17.15%
Cagr3y	-3.85%
Cagr5y	-16.33%
Div CAGR3	-12.64%
Div CAGR5	8.45%
EPS Growth	-10.05
EPS Growth Q	6.75
EPS Growth Quarters	3
EPS Growth Years	0
EPS Growth3 Y	4.55
EPS Growth5 Y	5.19
FCF Growth	-52.2%
FCF Growth Q	-91.49%
FCF Growth5 Y	17.58%
OCF Growth	10.76%
OCF Growth Q	-29.13%
OCF Growth3 Y	9.65%
OCF Growth5 Y	10.29%
Revenue Growth	14.73x
Revenue Growth Q	15.48x
Revenue Growth Quarters	8x
Revenue Growth Years	11x
Revenue Growth3 Y	10.21x
Revenue Growth5 Y	20.81x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	CNY 0.55
Assets	CNY 28.6B
Cash	CNY 3B
Current Assets	CNY 9.1B
Current Liabilities	CNY 8.4B
Debt	CNY 7.1B
Debt EBITDA	CNY 2.17
Debt Equity	CNY 0.41
Debt FCF	CNY 25.35
Equity	CNY 17.1B
Interest Coverage	10.34
Liabilities	CNY 11.4B
Long Term Assets	CNY 19.5B
Long Term Liabilities	CNY 3.1B
Net Cash	CNY -4.1B
Net Cash By Market Cap	CNY -8.94
Net Debt EBITDA	CNY 1.33
Net Debt Equity	CNY 0.24
Net Debt FCF	CNY 14.72
Tangible Book Value	CNY 11.8B
Tangible Book Value Per Share	CNY 6.42
WACC	7.95

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.08
Inventory Turnover	6.69
Net Working Capital	CNY 2.6B
Quick ratio	0.75
Working Capital	CNY 680.2M
Working Capital Turnover	CNY 7.59

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.78%
Dividend Growth	0%
Dividend Growth Years	0%
Dividend per share	CNY 0.2
Dividend Years	7
Dividend Yield	0.74%
Ex Div Date	2025-07-04
Last Dividend	CNY 0.2
Payout Frequency	Annual
Payout Ratio	31.73%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	17.14%
200-day SMA	30.11
3Y total return	-11.13%
50-day SMA	28.68
50-day SMA vs 200-day SMA	50under200
5Y total return	-58.98%
All Time High	108.7
All Time High Change	-74.97%
All Time High Date	2021-08-05
All Time Low	4.08
All Time Low Change	566.26%
All Time Low Date	2019-01-28
ATR	1.18
Beta	0.83
Beta1y	0.54
Beta2y	0.92
Ch YTD	-4.29
High	28.25
High52	37.63
High52 Date	2025-09-18
High52ch	-27.69%
Low	27.17
Low52	21.99
Low52 Date	2025-05-19
Low52ch	23.74%
Ma50ch	-5.12%
Price vs 200-day SMA	-9.62%
RSI	36.98
RSI Monthly	46.82
RSI Weekly	43.45
Sharpe ratio	0.59x
Sortino ratio	1.1
Total Return	-0.04%
Tr YTD	-4.29
Tr1m	-9.6%
Tr1w	-3.17%
Tr3m	-9.9%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	CNY 2.1B
Operating Income Growth	12.25
Operating Income Growth Q	6.35
Operating Income Growth3 Y	5.26
Operating Income Growth5 Y	12.26
Operating margin	14.22

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1,260,371,742%
Net Borrowing	926,790,368
Shares Insiders	7.57%
Shares Institutions	21.05%
Shares Out	1,830,020,328
Shares Qo Q	1.1%
Shares Yo Y	0.78%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	CNY 280.2M
Average Volume	37,190,869.25x
Bv Per Share	8.99
CAPEX	CNY -2.7B
Ch1m	-9.6
Ch1w	-3.17
Ch1y	16.18
Ch3m	-9.9
Ch3y	-13.43
Ch5y	-60.24
Ch6m	-14.08
Change	-3.06%
Change From Open	-3.44
Close	28.07
Days Gap	0.39
Depreciation Amortization	1,038,701,059
Dollar Volume	994,499,296.8
Earnings Date	2026-04-29
EBIT	CNY 2.1B
EBITDA	CNY 3.1B
EPS	CNY 0.95
F Score	7
FCF	CNY 280.2M
FCF EV Yield	0.55x
FCF Per Share	CNY 0.15
Financing CF	1,581,593,964
Fiscal Year End	December
Founded	2,004
Goodwill	3,535,087,310
Graham Number	15.06609
Graham Upside	-44.63
Income Tax	CNY 375.9M
Investing CF	-3,404,965,798
Is Primary Listing	1
Last Earnings Date	2026-04-29
Last Report Date	2026-03-31
Last Split Date	2023-07-27
Last Split Type	Forward
Lynch Fair Value	CNY 5.16
Lynch Upside	-81.04
Ma150	30.19
Ma150ch	-9.88%
Ma20	30
Ma20ch	-9.28%
Net CF	1,113,554,467
Next Earnings Date	2026-08-24
Open	28.18
P FCF Ratio	164.6
P OCF Ratio	15.52
Payment Date	2025-07-04
Position In Range	3.7
Ppne	12,194,464,006
Price Date	2026-05-08
Price EBITDA	CNY 14.82
Ptbv Ratio	3.92
Relative Volume	1.01x
Revenue	14,574,689,567x
Tax By Revenue	2.58x
Tax Rate	19.16%
Tr6m	-14.08%
Volume	36,549,037
Z Score	3.7

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

SHE/300759 dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+0.7%

$0.20 annual per share

Payout ratio

+31.7%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+8.4%

0 consecutive years of growth

Total shareholder yield

-0.0%

Next ex-dividend date: 2025-07-04

Performance

SHE/300759 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns SHE/300759?

Insider, institutional, and short-interest positioning.

Institutional ownership

+21.0%

Share of float held by funds and institutions

Insider ownership

+7.6%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+0.8%

Negative means the company is buying back shares.

Technical

SHE/300759 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

37.0

Neutral momentum band

Price vs 200-day MA

-9.6%

50/200-day relationship not available

Beta (5Y)

0.83

Moves roughly with the market

Sharpe ratio

0.59

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About SHE/300759

Hub-level FAQ points readers to the deeper analysis pages.

What is the current she/300759 stock rating?

she/300759 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full she/300759 analysis?

The full report lives at /stocks/she/300759/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for she/300759?

The latest report frames she/300759 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the she/300759 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.